Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

Abstract

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of oesophageal cancer was published in 2016, and covered the management and treatment of local/ locoregional disease, limited disease, locally advanced disease and the management of advanced/metastatic disease. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting immediately after the JSMO Annual Meeting in 2018. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic oesophageal cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic oesophageal cancer representing the oncological societies of Japan (JSMO), China (CSCO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.

Treatment pattern and overall survival in esophageal cancer during a 13-year period: A nationwide cohort study of 6,354 Korean patients

“…[17] In the European and Japanese guidelines, perioperative chemotherapy is recommended for locally advanced AC and neo-adjuvant chemotherapy is recommended for locally advanced SCC, [18] and definitive CCRT revealed similar survival rates. [19,20] However, in Taiwan Cancer Registry data, esophagectomy with neoadjuvant therapy showed better survival than definitive CCRT. [21] In this real world data, the proportion of patient undergoing CCRT in stage II-III rose from 17.1% to 43.0%, but the clinical outcomes was disappointing and worse than documented in previous studies.…”

The Clinical Impact of the Age-adjusted Charlson Comorbidity Index on Esophageal Cancer Patients Who Receive Curative Treatment

“…estimated 470,000 new esophageal cancer cases and 400,000 deaths occurred worldwide every year (1,2). Esophagectomy with perioperative chemotherapy is the standard treatment for locally advanced esophageal cancer (3)(4)(5). However, almost half of patients suffer recurrence, even after curative surgery.…”

Development ofHER2-targeted Therapies for Gastrointestinal Cancer

“…13,56 Trastuzumab plus chemotherapy is recommended in patients with HER2-positive OAC based on the results of ToGA trial. 57 In OSCC, the frequency of HER2 amplification is much lower than that observed for OAC. In a genomic landscape study in Japan, HER2 amplification was detected in only 2.3% of OSCC cases.…”